Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 701-305-8 | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Link to relevant study record(s)
- Endpoint:
- basic toxicokinetics
- Type of information:
- read-across from supporting substance (structural analogue or surrogate)
- Adequacy of study:
- supporting study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- data from handbook or collection of data
- Remarks:
- peer-reviewed data
- Principles of method if other than guideline:
- Review evaluating peer-reviewed data
- Type:
- absorption
- Results:
- PAH are absorbed through the pulmonary tract, the gastrointestinal tract, and the skin. Absorption rate from lung depends on type of PAH. Gastrointestinal absorption is rapid in rodents with metabolites returning to the intestine via biliary excretion.
- Type:
- distribution
- Results:
- PAH are widely distributed throughout the organism after administration by any route and are found in almost all internal organs, but particularly those rich in lipids.
- Type:
- metabolism
- Results:
- Metabolism is via intermediary epoxides which are further transformed by rearrangement or hydration to phenols or dihydrodiols. Secondary oxidation yield tetrols. Hydroxylated metabolites can be conjugated with sulphuric or glucuronic acid or glutathione.
- Type:
- excretion
- Results:
- PAH metabolites and their conjugates are excreted via the urine and faeces. Conjugates may be hydrolysed by gut flora after biliary excretion and be reabsorbed. With increasing size, excretion into faeces increases. PAH seem not to persist in the body.
- Endpoint:
- dermal absorption in vitro / ex vivo
- Type of information:
- experimental study
- Adequacy of study:
- supporting study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- study well documented, meets generally accepted scientific principles, acceptable for assessment
- Qualifier:
- no guideline available
- Principles of method if other than guideline:
- Skin model/in-vitro blood perfusion model: by de Lange et al. 1991, J. Pharmacol. Toxicol. Methods 27, 71-77
- GLP compliance:
- no
- Specific details on test material used for the study:
- - Name of test material (as cited in study report): coal tar
- Physical state: liquid, viscous - Radiolabelling:
- no
- Species:
- pig
- Strain:
- other: domestic
- Sex:
- not specified
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Slaughterhouse: no details
- Weight at study initiation: 75 – 100 kg - Type of coverage:
- open
- Vehicle:
- unchanged (no vehicle)
- Duration of exposure:
- average perfusion time: 250 min
- Doses:
- ~11 mg tar/cm² [100 %]
=================================================================
Substance: Content in coal tar [%] / Single PAH dose [µg/cm2];
fluorene: 2.1 / 230
phenanthrene: 6.8 / 750
anthracene: 3.7 / 410
fluoranthene: 4.0 / 440
pyrene: 2.1 / 230
benzo[b]fluoranthene: 0.9 / 90
benzo[k]fluoranthene: 0.4 / 44
benzo[a]pyrene: 0.9 / 90
indeno[123-cd]pyrene: 0.6 / 66
dibenz[ah]anthracene: 0.4 / 44
Total: ~22 % / ~2400 µg/cm2
=================================================================== - No. of animals per group:
- 5 pig ears per treatment
- Control animals:
- no
- Details on study design:
- DOSE PREPARATION
not applicable, neat substance tested
APPLICATION OF DOSE: topical to the ear
VEHICLE: not applicable
TEST SITE
- Preparation of test site: no particular action
- Area of exposure: 6 x 4 cm²
- Type of cover / wrap if used: none
REMOVAL OF TEST SUBSTANCE
- Perfusion: until perfusion pressure became too high (> 70 mm Hg), max. 250 min.
- Removal of protecting device: not relevant
- Washing procedures and type of cleansing agent: not relevant, termination of test
- Time after start of exposure: max. 250 min
SAMPLE COLLECTION
- Collection of blood: 200 min, for pyrene: complete kinetics with 10 – 11 time intervals up to 200 – 250 min
ANALYSIS
- Blood samples (10 ml): Reversed-phase HPLC after 3-fold extraction with n-hexane, evaporation of the solvent and re-dissolution of the residues in methanol (2 ml)
- Limits of detection and quantification: see above under Test material
- The method for analysis of the 10 PAHs has an average coefficient of variation of 14.4 %.
- Recovery ranged from 45 % for dibenzo[a]anthracene to 97 % for anthracene.
- Limits of detection:
[pmol/ml blood]
===============================
fluorene 53.0
phenanthrene 1.7
anthracene 2.0
fluoranthene 51.0
pyrene 2.7
benzo[b]fluoranthene 7.8
benzo[k]fluoranthene 0.3
benzo[a]pyrene 6.3
indeno[123-cd]pyrene 8.3
dibenzo[ah]anthracene 16.5
===============================
STATISTICS:
Paired t-test to determine whether the dermal absorption of the various PAH was statistically different from pyrene absorption. - Details on in vitro test system (if applicable):
- In-vitro blood perfusion model:
Five ears from domestic pigs were used to study the uptake of 10 PAH in blood after coal-tar application.
The treatment started after 30 min pre-perfusion with oxygenated blood. Perfusion at 30 °C with heparinized pig blood collected from the pigs.
Coal tar was applied to a skin area of 6x4 cm² with an average dose of 11 mg/cm².
Simultaneously, functional control measurements were conducted to assure the physiological integrity of the organ, including blood pressure, blood flow, and glucose uptake. - Total recovery:
- see also above "Details of Study Design"
- Limit of detection (LOD): see under "Test materials" - Key result
- Time point:
- 200 min
- Dose:
- 11 mg coal tar (230 µg fluorene)/cm²
- Parameter:
- rate
- Absorption:
- ca. 71 other: ng/(h cm²)
- Remarks on result:
- other: absorption rate for fluoranthene
- Key result
- Time point:
- 200 h
- Dose:
- 11 mg coal tar (750 µg phenanthrene)/cm²
- Parameter:
- rate
- Absorption:
- ca. 103 other: ng/(h cm²)
- Remarks on result:
- other: absorption rate for phenanthrene
- Key result
- Time point:
- 200 min
- Dose:
- 11 mg coal tar (410 µg anthracene)/cm²
- Parameter:
- rate
- Absorption:
- ca. 19.5 other: ng/(h cm²)
- Remarks on result:
- other: absorption rate for anthracene
- Key result
- Time point:
- 200 min
- Dose:
- 11 mg coal tar (440 µg fluoranthene)/cm²
- Parameter:
- rate
- Absorption:
- ca. 21 other: ng/(h cm²)
- Remarks on result:
- other: absorption rate for fluoranthene
- Key result
- Time point:
- 200 min
- Dose:
- 11 mg coal tar (230 µg pyrene)/cm²
- Parameter:
- rate
- Absorption:
- ca. 12 other: ng/(h cm²)
- Remarks on result:
- other: absorption rate for pyrene
- Key result
- Time point:
- 200 min
- Dose:
- 11 mg coal tar (90 µg benzo[a]pyrene)/cm²
- Parameter:
- rate
- Absorption:
- ca. 0.76 other: ng/(h cm²)
- Remarks on result:
- other: absorption rate for benzo[a]pyrene)
- Key result
- Time point:
- 200 min
- Dose:
- 11 mg coal tar (44 µg dibenz[ah]anthracene)/cm²
- Parameter:
- rate
- Absorption:
- ca. 0.28 other: ng/(h cm²)
- Remarks on result:
- other: absorption rate for dibenz[ah]anthracene
- Conversion factor human vs. animal skin:
- not applicable
- Endpoint:
- dermal absorption in vitro / ex vivo
- Type of information:
- experimental study
- Adequacy of study:
- supporting study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- study well documented, meets generally accepted scientific principles, acceptable for assessment
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 428 (Skin Absorption: In Vitro Method)
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- other: OECD (1996): Dermal delivery and percutaneous absorption: in-vitro method. OECD guideline for testing chemicals – Proposal for new guideline. OECD, Paris
- GLP compliance:
- not specified
- Specific details on test material used for the study:
- Mixtuer of 13 PAH: Composition
Name CAS-No. Mol. Mass Applied dose[nmol/cm2]
=========================================================
Naphthalene 91-20-3 128.2 160.0
Acenaphthene 83-32-9 154.2 120.0
Fluorene 86-73-7 166.2 23.1
Anthracene 120-12-7 178.2 15.1
Phenanthrene 85-01-8 178.2 12.1
Pyrene 129-00-0 202.3 9.3
Benz[a]anthracene 56-55-3 228.3 8.5
Chrysene 218-01-9 228.3 6.5
Benzo[b]fluoranthene 205-99-2 252.3 16.5
Benzo[k]fluoranthene 207-08-9 252.3 6.3
Benzo(a)pyrene 50-32-8 252.3 6.1
Dibenz[a,h]anthracene 191-24-2 278.4 7.5
Benzo[ghi]perylene 53-70-3 276.3 6.9
======================================================= - Radiolabelling:
- no
- Species:
- monkey
- Strain:
- other: Ceropithecus aetops
- Sex:
- not specified
- Details on test animals or test system and environmental conditions:
- Not given, from a medical facility producing poliovirus vaccine
- Type of coverage:
- open
- Vehicle:
- other: 1.) Lubricating oil: commercial lubricator for engines (PAHs below detection limits) and 2.) Artificial sweat was simulated by using 2.5 g NaH2PO4, 0.2 g triolein, 2 drops of Tween 85 per 1 litre water, pH 5.2 with HCl
- Duration of exposure:
- static up to 72 h
- Doses:
- Mixture of PAH:
==============================
Substance: applied dose [ng/cm²];
Acenaphthene: 18,505;
Fluorene: 3,840;
Anthracene: 2,691;
Phenanthrene: 2,157;
Pyrene: 1,881;
Benz[a]anthracene: 1,940;
Chrysene: 1,484;
Benzo[b]fluoranthene: 4,163;
Benzo[a]pyrene: 1,535;
Dibenz[a,h]anthracene: 2,088;
Benzo[ghi]perylene: 1,906
==============================
Note: In this study additional lower-molecular-weight PAHs have been included not relevant to CTPht, and therefore not listed. - Control animals:
- no
- Details on study design:
- DOSE PREPARATION
- Method for preparation of dose suspensions: 13 PAH were dissolved/dispersed in either aceton or lubricating oil in concentrations that after addition to the diffusion cell, doses was as given under Test material or Doses
- Method of storage:
APPLICATION OF DOSE:
- PAH mixture: 1.) 30 µl PAH acetone solution were placed in the diffusion cell, and the acetone was allowed to evaporate. Then a few drops of artificial sweat were added.
2.) PAH mixture dispersed in lubricating oil was placed into the diffusion cell
TEST SITE
- Preparation of test site:
- Area of exposure: 1.77 cm2
REMOVAL OF TEST SUBSTANCE: diffusion cell was dismantled at the end of the test and the skin sample was disposed as waste
SAMPLE COLLECTION
- Receiving liquid from diffusion cells: ten 1 ml samples were taken after initiation of skin contact at various intervals from 20 min to 72 h (see Report Fig. 1-6)
SAMPLE PREPARATION
- Preparation details: purification of media samples with acetonitrile in the presence of NaCl,
ANALYSIS
- Method type(s) for identification: reverse-phase HPLC; Column: LC-PAH Supelchem column (25 cm long, 4.6 mm i.d., 5 µm grain size), Eluent: acetonitrile-water gradient; Detector: programmable excitation and emission wavelength spectro-fluorimeter Shimadzu RF 551
- Limits of detection [nmol/L]: naphthalene 25.8, acenaphthene 1.67, fluorene 7.5, phenanthrene 2.80, anthracene 0.56, pyrene 0.49, benzo[a]anthracene 1.32, and chrysene 0.45.
- Coeffcient of variation of the analytical method: 10.8 % - Details on in vitro test system (if applicable):
- SKIN PREPARATION
- Source and type of skin: Full-thickness skin from abdomen of Ceropithecus aetops
- Membrane integrity check: Barrier integrity of skin specimens was demonstrated by measuring 3H-H2O penetration after treatment with acetone.
- Storage conditions: Skin samples were frozen and stored for a few days.
PRINCIPLES OF ASSAY
- Diffusion cell: Static diffusion cell (FDC 400, Crown Glass, N.J. USA), exposure area 1.77 cm² (diameter 1.5 cm).
- Receptor fluid: (volume not specified): saline/bovine serum albumin solution (4 % BSA) containing gentamycin sulphate as antibiotic.
The PAH mixture was applied
1. in 30 µl acetone followed by addition of artificial sweat after solvent evaporation (6 diffusion cells)
2. in lubricating oil (7 diffusion cells)
- Static system: yes
- Test temperature: diffiusion cell kept at 37 °C resulting in a skin temperature of 32 °C
- Occlusion: no - Dermal irritation:
- not examined
- Absorption in different matrices:
- Kinetic key data from in-vitro studies on monkey skin specimens (exposure medium lubrication oil or artificial sweat/acetone):
==============================
Average steady state absorption rate [ng/(h*cm²)]
------------------------------------------------------------
Lubricating oil / Acetone/sweat
Acenaphthene: 34 / 147;
Fluorene: 6 / 24;
Anthracene: 2.1 / 9.4;
Phenanthrene: 1.0 / 5.7;
Pyrene: 0.3 / 7.8;
Benz[a]anthracene: n.d. / 3.2;
Chrysene: 0.3 / 0.8;
Benzo[b]fluoranthene: n.d. / 0.9;
Benzo[a]pyrene: n.d. / 0.4;
Dibenzo(a,h)anthracene n.d / n.d;.
Results for the additional PAH tested in the study are not reported.
==============================
Absorption percentage of selected components is calculated from steady state absorption rate, exposure time (8 h corresponding to a work shift) and dose. - Key result
- Dose:
- 18.5 µg/cm²
- Parameter:
- percentage
- Absorption:
- ca. 6.4 %
- Remarks on result:
- other: absorption period 8 hrs; calculated from steady-state flux after a lag phase of ca. 3 hrs
- Remarks:
- substance acenaphthene; absorption from artificial sweat/acetone
- Key result
- Dose:
- 3.84 µg/cm²
- Parameter:
- percentage
- Absorption:
- ca. 5 %
- Remarks on result:
- other: absorption period 8 hrs; calculated from steady-state flux after a lag phase of ca. 5 hrs
- Remarks:
- substance fluorene; absorption from artificial sweat/acetone
- Key result
- Dose:
- 2.69 µg/cm²
- Parameter:
- percentage
- Absorption:
- ca. 2.8 %
- Remarks on result:
- other: absorption period 8 hrs; calculated from steady-state flux after a lag phase of ca. 13 hrs
- Remarks:
- substance anthracene; absorption from artificial sweat/acetone
- Key result
- Dose:
- 2.16 µg/cm²
- Parameter:
- percentage
- Absorption:
- ca. 2.1 %
- Remarks on result:
- other: absorption period 8 hrs; calculated from steady-state flux after a lag phase of ca. 11 hrs
- Remarks:
- substance phenanthrene; absorption from artificial sweat/acetone
- Key result
- Dose:
- 1.88 µg/cm²
- Parameter:
- percentage
- Absorption:
- ca. 3.3 %
- Remarks on result:
- other: absorption period 8 hrs; calculated from steady-state flux after a lag phase of ca. 25 hrs
- Remarks:
- substance pyrene; absorption from artificial sweat/acetone
- Key result
- Dose:
- 1.48 µg/cm²
- Parameter:
- percentage
- Absorption:
- ca. 0.4 %
- Remarks on result:
- other: absorption period 8 hrs; calculated from steady-state flux after a lag phase of ca. 24 hrs
- Remarks:
- substance chrysene; absorption from artificial sweat/acetone
- Key result
- Dose:
- 1.54 µg/cm²
- Parameter:
- percentage
- Absorption:
- ca. 0.2 %
- Remarks on result:
- other: absorption period 8 hrs; calculated from steady-state flux after a lag phase of ca. 32 hrs
- Remarks:
- substance benzo[a]pyrene; absorption from artificial sweat/acetone
- Executive summary:
Materials and methods
This in-vitro diffusion system is a suitable technique to demonstrate penetration through the skin, in particular for comparative purposes (species differences and/or different exposure scenarios). In this case, reasons for selection of monkey: similarity of percutaneous penetration through human and monkey skin, based on published data.
Results and discussion
The penetration constant Kp values of compounds resulted in a significant slower passage from the oil matrix than from the acetone/sweat combination (p <=0.05) (although the SD was very high, see Tab. 2 and 3): for naphthalene, acenaphthene, fluorene, anthracene and phenanthrene, the penetration was about 4 to 5 times less in the oil matrix than in the solvent/sweat combination. For pyrene and chrysene the factor was on the order of 3. This is also reflected in the significant extended lag-time for the oil matrix.
After the lag-time, the increases in concentration on the receptor side were nearly linear for some 70 h except for naphthalene which did not accumulate any more after 30 to 40 h (see Report Fig. 6).
Chrysene was found to be below or at the border of detection limit, while a passage for the other PAH with >=4 rings could only be demonstrated when they were applied in acetone/sweat mixture.
Referenceopen allclose all
Initial absorption rates of 10 PAHs from coal tar applied to the perfused pig ear
|
Absorption fluxes at 200 min p.a. |
|
|
pmol/(h*cm²) |
ng/(h*cm²) |
Fluorene |
430 |
approx. 71 |
Phenanthrene |
580 |
approx. 103 |
Anthracene |
110 |
approx. 19.5 |
Fluoranthene |
105 |
approx. 21 |
Pyrene |
60 |
approx. 12 |
Benzo[b]fluoranthene |
3 |
approx. 0.76 |
Benzo[k]fluoranthene |
1 |
approx. 0.25 |
Benzo[a]pyrene |
3 |
approx. 0.76 |
Indeno[1,2,3-cd]pyrene |
1 |
approx. 0.28 |
Dibenz[a,h]anthracene |
1 |
approx. 0.28 |
The mean absorption fluxes [pmol/(h*cm2)] at 200 min after application of coal tar varied strongly between the 10 PAH.
Furthermore, variation between ears was high, too: for pyrene, for example, the flux ranged between 6 and 155 pmol/(h*cm2) and the cumulative uptake after 200 min was between 26 and 193 pmol/cm2. This was not caused by differences in dosing: applied amounts were high overdoses, because 0.2 % of each PAH was absorbed through the skin after 200 min.
The relative cumulative uptake (in relation to pyrene) was 0.01 for indeno[123-cd]pyrene to 12 for phenanthrene, for each PAH except fluoranthene, statistically different from pyrene uptake (p= 0.01). The inter-ear variation was relatively small when the absorbed amount was related to pyrene, indicating that the relative absorption fluxes of the various PAH were quite constant.
TEST RESULTS are expressed as
1. specific steady-state absorption flux F [nmol/(cm2*h)],
2. a penetration constant Kp [cm/h], a dose-independent parameter which results from division of F by the dose and
3. the lag time [h].
After the lag time, the increase in concentration on the receptor side were nearly linear for some 70 h except for naphthalene, which did not accumulate any more after 30 to 40 h.
Tab.
1: Kinetic
key data from in-vitro studies on monkey skin specimens: specific
steady-state absorption flux F [nmol/(cm2*h)],
penetration constant
Kp [cm/h], and
the lag time [h]
|
Lubricating oil |
Acetone/ |
Lubricating oil |
Acetone/ |
Lubricating oil |
Acetone/ |
|
Average steady-state absorption rate [ng/(h*cm2] |
Average Kp |
Average |
|||
Naphthalene |
35 |
129 |
1.87 |
6.31 |
4.9 |
1.2 |
Acenaphthene |
34 |
147 |
1.72 |
7.80 |
8.4 |
2.3 |
Fluorene |
6 |
24 |
1.64 |
6.56 |
5.7 |
4.2 |
Anthracene |
2.1 |
9.4 |
0.93 |
3.97 |
17.6 |
12.9 |
Phenanthrene |
1.0 |
5.7 |
0.5 |
2.63 |
15.2 |
11.0 |
Pyrene |
0.3 |
7.8 |
0.17 |
4.13 |
13.4 |
24.5 |
Benz[a]anthracene |
n.d. |
3.2 |
n.d. |
1.72 |
-- |
27.1 |
Chrysene |
0.3 |
0.8 |
0.22 |
0.57 |
26.1 |
23.8 |
Benzo[b]fluoranthene |
n.d. |
0.9 |
n.d. |
0.09 |
n.d. |
22.5 |
Benzo[k]fluoranthene |
n.d. |
0.4 |
n.d. |
0.09 |
n.d. |
23.8 |
Benzo(a)pyrene |
n.d. |
0.4 |
n.d. |
0.23 |
n.d. |
31.2 |
Dibenzo[a,h]anthracene |
n.d. |
n.d. |
n.d. |
n.d |
n.d. |
n.d. |
Benzo[ghi]perylene |
n.d. |
n.d. |
n.d. |
n.d |
n.d. |
n.d. |
n.d. = not detected in receptor fluid (see Report, Tab. 2 + 3)
|
PASSAGES estimated from Fig. 1, 2, 4, and 6 and Tab. 1):
|
OIL MATRIX |
ACETONE/SWEAT |
|
Passage in % dose after 24 h |
|
Naphthalene*) |
1.5 |
5 |
Acenaphthene |
2.0 |
15.0 |
Fluorene |
1.7 |
10.0 |
Anthracene |
1.2 |
3.0 |
Phenanthrene |
0.4 |
2.5 |
Pyrene |
0.5 |
1.8 |
Chrysene |
0.1 |
0.25 |
*) For naphthalene after 10 h /data from Report, Fig. 1- 4, 6 and 7 and Tab. 1)
The
average skin absorption of aromatic components was significantly delayed
when incorporated in an oil matrix, at factors from about 3 to 7 for
individual substances as compared to application in acetone-artificial
sweat solution. For benz[a]anthracene, benzo[b]- and
benzo[k]fluoranthene as well as benzo[a]pyrene
it was possible to demonstrate a passage through the skin only when
applied in acetone/sweat mixture (Report, Tab. 3, and p. 530). No
passage was found for dibenz[a,h]anthracene and benzo[g,h,i]perylene.
Description of key information
PAH are absorbed rapidly through the
pulmonary tract, the gastrointestinal tract, and to a much lesser extent
through skin. Metabolism is complex resulting mostly in hydroxylated
species which in part may further be conjugated. Excretion is via urine,
bile and faeces. Conjugates excreted into bile can be hydrolysed in the
gut and be reabsorbed.
Absorption through human skin will be not more than 2 % within and after
8 h of exposure. Permeation through rat skin is much more pronounced
(ca. 8 fold) compared to human skin.
Regarding the highly inert matrix of the substance Pitch,
coal tar, high-temp., < 1% 4- to 5-membered condensed ring aromatic
hydrocarbons [EC no. 701-305-8] (CTPhtht), the behaviour of the
substance as such will be different from the biological fate of its
individual constituents (5- and 6-ring PAH).
Key value for chemical safety assessment
- Bioaccumulation potential:
- no bioaccumulation potential
Additional information
The substance Pitch, coal tar, high-temp., < 1% 4- to 5-membered condensed ring aromatic hydrocarbons [EC no. 701-305-8] (CTPhtht), is a UVCB and consists of a complex and variable combination of polycyclic aromatic hydrocarbons (PAH). Substance matrix is composed of highly condensed ring aromatic systems because the substance is obtained as residue from a distillation process at temperatures up to > 550 °C.
The substance fraction that can be distilled from the material up to > 500 °C is only 5 - 6 %. The percentage of substances that can be identified by GC analysis is < 1 %. These components are essentially PAH consisting of 5- and 6-ring-condensed aromatic hydrocarbons (PAH). Concentrations of individual substances range from < 0.01 to ca. 0.2 % (w/w). Concentration of benzo[a]pyrene is ca. 0.04 % while EPA PAH sum up to ca. 0.4 %.
Taking into account the highly inert matrix, the low water solubility (clearly below 0.2 mg/L) and the low percentage of toxicologically relevant constituents, the toxicokinetic characteristics of the substance as such will not be very well represented by individual constituents. The substance itself is assessed as not being biologically available and not being well absorbed and metabolised. Constituents will only be released from the substance in very low amounts. These will be 5- and 6-ring PAH.
Therefore, the fate and properties of the substance as well as adverse effects in biological systems will be characterised on the one hand by the inert matrix of CTPhtht, in combination with its high carbonisation in the production process and the low solubility in aqueous and in organic media. On the other hand, PAH are present as constituents and may be released to some even if rather low extent. The poor bioavailability of the pitch matrix will reduce effects observed with neat individual PAH, hence the toxicokinetic characteristics of single PAH can be taken for granted as "worst case". In order to characterise toxicokinetics at all, some higher PAHs may be used as relevant constituents in CTPhtht.
Toxicokinetics of PAH
Toxicokinetic characteristics of PAH are reported based on a review of the WHO 1998/2003.
Absorption
PAH are absorbed through the pulmonary tract, the gastrointestinal tract, and the skin. The degree of absorption may be different for individual substances. The rate of absorption from the lungs depends on the type of PAH, the size of the particles on which they are adsorbed, and the composition of the adsorbent. PAH adsorbed onto particulate matter are cleared from the lungs more slowly than free hydrocarbons.
Gastrointestinal absorption in rodents has been reported to be high. Fractional absorption of lower-molecular-weight PAHs, e.g. two-ring aromatics such as naphthalene, may be more complete than that of higher-molecular-weight PAHs, e.g. five-ring aromatics such as benzo[a]pyrene. Effective absorption by the different routes is also evidenced by observation of systemic toxicity following exposure by the different routes. Absorption from the gastrointestinal tract occurs rapidly in rodents, but metabolites return to the intestine via biliary excretion.
Distribution
PAH are widely distributed throughout the organism after administration by any route and are found in almost all internal organs, but particularly those rich in lipids. Intravenously injected PAH are cleared rapidly from the bloodstream of rodents but can cross the placental barrier and have been detected in foetal tissues.
Studies with 32P-postlabelling for the detection of DNA-adducts after percutaneous absorption of mixtures of PAH in rodents showed that components of the mixtures reach the lungs, where they became bound to DNA.
Metabolism
The metabolism of PAH to more water-soluble derivatives, which is a prerequisite for their excretion, is complex. In general, parent compounds are converted into intermediate epoxides (a reaction catalysed by cytochrome P450-dependent mono-oxygenases), which are further transformed by rearrangement or hydration to yield phenols or diols. In following steps conjugation by glutathione, sulphate or glucuronic acid may occur. Alternatively or in addition, a second oxidation at another position of the aromatic system is possible to yield tetrols, which can themselves be conjugated with sulphuric or glucuronic acids or with glutathione. Most metabolism results in detoxification, but some PAH are activated to DNA-binding species, principally diol epoxides, which can initiate tumours.
Excretion
PAH metabolites and their conjugates are excreted via the urine and faeces, but conjugates excreted into the bile can be hydrolysed by enzymes of the gut flora and be reabsorbed. It can be inferred from the available information on the total human body burden that PAH do not persist in the body and that turnover is rapid. This inference excludes those PAH moieties that become covalently bound to tissue constituents, in particular to nucleic acids, and are not removed by repair.
References
WHO (1998). Selected non-heterocyclic polycyclic aromatic hydrocarbons. Environmental Health Criteria 202, Geneva, Switzerland, WHO (World Health Organisation) 1998
WHO (2003). HEALTH RISKS OF PERSISTENT ORGANIC POLLUTANTS FROM LONG-RANGE TRANSBOUNDARY AIR POLLUTION, JOINT WHO/CONVENTION TASK FORCE ON THE HEALTH ASPECTS OF AIR POLLUTION. WHO Regional Office for Europe, World Health Organization 2003
It should be kept in mind that the properties described above relate to individual PAH. CTPhtht, as such will behave quite differently and will show a highly inert behaviour.
Dermal absorption
Studies of Van Rooij 1995 and Sartorelli 1999 show that higher molecular weight PAH are absorbed at a much lesser rate than lower molecular weight PAH. For absorption through pig ear (Van Rooij) [1] and full thickness skin from the abdomen of monkeys (Ceropithecus aetops) (application in artificial sweat) (Sartorelli) [2], differences in absorption rates from 0.8 ng/(h*cm²) [1] and 0.9 ng/(h*cm²) [2] for benzo[b]fluoranthene to not detectable [1] and [2] for dibenzo[a,h]anthracene and benzo[ghi]perylene were observed. In comparison, pyrene showed considerable higher absorption rates of 12 [1] and 7.8 [2] ng/(h*cm²).
In addition, observations from comparative in-vivo and in-vitro studies (human vs. rodent) on spiked creosote demonstrate that not more than 2 % of a dermal dose of a tar oil (creosote) will be absorbed through human skin within and after 8 hours of exposure (Fasano 2007). This will be a worst-case situation compared to dermal absorption of CTPhtht.
This indicates that absorption of CTPhtht through skin is highly limited. Single components (5- and 6-membered PAHJ) are absorbed very slowly. CTPhtht as such is composed of a highly inert matrix and will be absorbed through skin to a considerably lower extent.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.